Bayer's 2026 Tightrope: A Hold Rating Amidst Cash Burn and Pipeline Pressure

DZ Bank upgrades Bayer to 'Hold' citing calculable glyphosate risks and Crop Science valuation, but massive legal payouts and pharma patent cliffs loom.

A shift in analyst sentiment offers a fragile vote of confidence for Bayer, even as the company navigates a perfect storm of legal payouts and a pressing need for new pharmaceutical blockbusters. DZ Bank upgraded its rating on the stock from "Sell" to "Hold," raising its price target to 44 euros. Analyst Peter Spengler cited a higher valuation multiple for the Crop Science division looking ahead to 2027 and lower estimates for pension provisions as key reasons. For the current 2026 fiscal year, he forecasts earnings per share of 4.35 euros.

This modest optimism hinges on a perceived shift regarding the glyphosate litigation overhang. The bank now views the long-standing legal risks as increasingly calculable due to pursued settlements, potentially allowing investors to refocus on the group's fundamental earning power. Yet the scale of the ongoing financial drain remains staggering. The company has earmarked roughly five billion euros for lawsuit-related payouts in the glyphosate complex this year alone, a figure set to push free cash flow deep into negative territory.

Operational stability is the immediate test. Despite discussions around potential US import tariffs on pharmaceutical goods, Bayer is sticking to its 2026 guidance for an adjusted operating profit between 9.6 and 10.1 billion euros. The company believes an existing trade agreement capping tariffs at 15 percent mitigates the risk. On Thursday, Bayer underscored its commitment to its key agricultural business by opening a new seed production innovation center at Iowa State University, highlighting the strategic importance of the US market for its Crop Science unit.

The pharmaceutical division faces its own critical timeline. With major drug patents expiring, the pipeline is under intense pressure to deliver. The prostate cancer drug Nubeqa, which has treated over 200,000 patients globally and expects approval in China this year, is central to the growth plan. Management aims for mid-single-digit growth in the pharma business from 2027 onward, targeting an operating margin above 30 percent by 2030. Nelson Ambrogio will take over leadership of the US pharmaceuticals division starting May 1 to help steer this effort.

Recent financial results lay bare the dual burden of operational performance and legal costs. For the 2025 business year, Bayer reported revenue of 45.6 billion euros but a net loss of 3.6 billion euros, heavily burdened by legal expenses of 6.2 billion euros. The dividend was cut to the legal minimum of 0.11 euros per share. On the balance sheet, net debt recently declined to 29.8 billion euros due to operational inflows and currency effects, yet the overall cash position remains strained.

The stock's muted reaction to the upgrade reflects this complex backdrop. Shares traded slightly lower around 40.30 euros, still about 18 percent below the February high of 49.17 euros. Investors are now looking to two near-term events for clearer signals. The virtual Annual General Meeting on April 24 will serve as a referendum on CEO Bill Anderson's strategy and includes a vote on the proposed 0.11 euro dividend. Shortly after, on May 12, the release of first-quarter 2026 figures will provide the first concrete data on whether cost-cutting programs and an operational uptick in agriculture are gaining tangible traction.